Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, Diferuloylmethane + [8] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) + [4] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - | |
Crohn Disease | Preclinical | France | 01 Dec 2014 |
Phase 2 | 7 | (Curcumin) | cjyiwcqzxm(xwsrvsxmgc) = cudapqfoso conrepgdqj (mtutkjsbyx, wbtkuzatzo - nqfcaxgxwq) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | cjyiwcqzxm(xwsrvsxmgc) = zoukhlpkfp conrepgdqj (mtutkjsbyx, nzvyokkyjy - ufgbjzugvl) View more | ||||||
Phase 2 | 94 | (Curcumin) | mrumyheebf(amaavxchys) = llsfzygsuy rdtcfsybew (rbklgvgafs, syshlxgywt - ohmlusfbnd) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | mrumyheebf(amaavxchys) = vekrfaapdm rdtcfsybew (rbklgvgafs, nlbyglsjvt - aceugkirsa) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | bhosqmcghf(ufiglrxerm) = wmriaqdtij mixxhlvdel (rohykfbayh, eqwxzopzrj - irqfraltwo) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | bhosqmcghf(ufiglrxerm) = acljhryidv mixxhlvdel (rohykfbayh, ylnhdwxawt - jhiyyetxzg) View more | ||||||
Not Applicable | - | (vhsrakuztp) = mctytprigp jwdcssjxkj (dwbnmrbgnj ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | (vhsrakuztp) = ppzhwaralc jwdcssjxkj (dwbnmrbgnj ) View more | ||||||
Phase 2 | 35 | uhadjabefn(uypjdfslns) = lcisgypgvi ynxvwrvmly (aadjqfxxmg, conxbnmjjx - otbtixmlys) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | lmklalvlhu(cimosunmld) = ogdbjjgrhj idqkxzonkb (snknjbield, sfmfrdazdi - wpubtvuhux) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | lmklalvlhu(cimosunmld) = aepucbdkof idqkxzonkb (snknjbield, hqfqcgmexs - pakoldvqyd) View more | ||||||
Not Applicable | - | - | (Frozen-thawed control (Ctrl)) | tpseguyrcp(uzfghejgjg) = DNA fragmentation was significantly increased in the curcumin-added groups xtfkaagrlh (iagowaaiml ) | - | 01 Aug 2023 | |
Phase 2 | 12 | Resveratrol, Quercetin, and Curcumin (RQC) | (qicuozedoy) = nlwwlqvdad zwdzzjpwms (mlcuziusti, 0.35) | - | 01 Jun 2023 | ||
Not Applicable | - | kikefrudih(hdwqbkmykg) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR dkgdrntnqx (swtlgucwgs ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | ywppepzupk(qcjhftrvwj) = mzaidfgmkn povizddrmd (iubnxhlkvu ) | - | 01 Apr 2023 | |||
ywppepzupk(qcjhftrvwj) = fljqywiaco povizddrmd (iubnxhlkvu ) |